Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis

Brain Behavior and Immunity, Journal Year: 2021, Volume and Issue: 101, P. 93 - 135

Published: Dec. 29, 2021

Language: Английский

---

Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments

Infectious Diseases, Journal Year: 2021, Volume and Issue: 53(10), P. 737 - 754

Published: May 22, 2021

Long COVID or post-COVID-19 syndrome first gained widespread recognition among social support groups and later in scientific medical communities. This illness is poorly understood as it affects COVID-19 survivors at all levels of disease severity, even younger adults, children, those not hospitalized. While the precise definition long may be lacking, most common symptoms reported many studies are fatigue dyspnoea that last for months after acute COVID-19. Other persistent include cognitive mental impairments, chest joint pains, palpitations, myalgia, smell taste dysfunctions, cough, headache, gastrointestinal cardiac issues. Presently, there limited literature discussing possible pathophysiology, risk factors, treatments COVID, which current review aims to address. In brief, driven by long-term tissue damage (e.g. lung, brain, heart) pathological inflammation from viral persistence, immune dysregulation, autoimmunity). The associated factors female sex, more than five early symptoms, dyspnoea, prior psychiatric disorders, specific biomarkers D-dimer, CRP, lymphocyte count), although research required substantiate such factors. preliminary evidence suggests personalized rehabilitation training help certain cases, therapeutic drugs repurposed other similar conditions, myalgic encephalomyelitis chronic syndrome, postural orthostatic tachycardia mast cell activation also hold potential. sum, this hopes provide understanding what known about COVID.

Language: Английский

---

Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection

JAMA Network Open, Journal Year: 2021, Volume and Issue: 4(10), P. e2128568 - e2128568

Published: Oct. 13, 2021

Importance

Short-term and long-term persistent postacute sequelae of COVID-19 (PASC) have not been systematically evaluated. The incidence evolution PASC are dependent on time from infection, organ systems tissue affected, vaccination status, variant the virus, geographic region.

Objective

To estimate system–specific frequency PASC.

Evidence Review

PubMed (MEDLINE), Scopus, World Health Organization Global Literature Coronavirus Disease, CoronaCentral databases were searched December 2019 through March 2021. A total 2100 studies identified cited references. Studies providing data in children adults included. Preferred Reporting Items for Systematic Reviews Meta-analyses (PRISMA) guidelines abstracting followed performed independently by 2 reviewers. Quality was assessed using Newcastle-Ottawa Scale cohort studies. main outcome diagnosed (1) laboratory investigation, (2) radiologic pathology, (3) clinical signs symptoms. classified system, ie, neurologic; cardiovascular; respiratory; digestive; dermatologic; ear, nose, throat as well mental health, constitutional symptoms, functional mobility.

Findings

From a identified, 57 with 250 351 survivors met inclusion criteria. mean (SD) age 54.4 (8.9) years, 140 196 (56%) male, 197 777 (79%) hospitalized during acute COVID-19. High-income countries contributed 45 (79%). median (IQR) proportion experiencing at least 1 54.0% (45.0%-69.0%; 13 studies) month (short-term), 55.0% (34.8%-65.5%; 38 to 5 months (intermediate-term), (31.0%-67.0%; 9 6 or more (long-term). Most prevalent pulmonary sequelae, neurologic disorders, health mobility impairments, general symptoms chest imaging abnormality (median [IQR], 62.2% [45.8%-76.5%]), difficulty concentrating 23.8% [20.4%-25.9%]), generalized anxiety disorder 29.6% [14.0%-44.0%]), impairments 44.0% [23.4%-62.6%]), fatigue muscle weakness 37.5% [25.4%-54.5%]), respectively. Other frequently reported included cardiac, dermatologic, digestive, disorders.

Conclusions Relevance

In this systematic review, than half experienced after recovery. most common involved abnormalities, These effects occur scale that could overwhelm existing care capacity, particularly low- middle-income countries.

Language: Английский

---

Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19

JAMA Network Open, Journal Year: 2021, Volume and Issue: 4(5), P. e2111417 - e2111417

Published: May 26, 2021

Infection with COVID-19 has been associated long-term symptoms, but the frequency, variety, and severity of these complications are not well understood. Many published commentaries have proposed plans for pandemic control that primarily based on mortality rates among older individuals without considering morbidity all ages. Reliable estimates such important patient care, prognosis, development public health policy.

Language: Английский

---

Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study

Journal of Infection, Journal Year: 2021, Volume and Issue: 82(3), P. 378 - 383

Published: Jan. 13, 2021

This study aims to analyze the incidence of Post-acute COVID-19 syndrome (PCS) and its components, evaluate acute infection phase associated risk factors.A prospective cohort adult patients who had recovered from (27th February 29th April 2020) confirmed by PCR or subsequent seroconversion, with a systematic assessment 10-14 weeks after disease onset. PCS was defined as persistence at least one clinically relevant symptom, abnormalities in spirometry chest radiology. Outcome predictors were analyzed multiple logistic regression (OR; 95%CI).Two hundred seventy seven mild (34.3%) severe (65.7%) forms SARS-CoV-2 evaluated 77 days (IQR 72-85) detected 141 (50.9%; 95%CI 45.0-56.7%). Symptoms mostly mild. Alterations noted 25/269 (9.3%), while radiographs 51/277 (18.9%). No baseline clinical features behaved independent development.A half COVID19 survivors. Radiological spirometric changes observed less than 25% patients. development.

Language: Английский

---

Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19

JAMA, Journal Year: 2021, Volume and Issue: 325(15), P. 1525 - 1525

Published: March 17, 2021

Little is known about long-term sequelae of COVID-19.

Language: Английский

---

Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study

BMJ, Journal Year: 2021, Volume and Issue: unknown, P. n1098 - n1098

Published: May 19, 2021

To evaluate the excess risk and relative hazards for developing incident clinical sequelae after acute phase of SARS-CoV-2 infection in adults aged 18-65.Retrospective cohort study.Three merged data sources from a large United States health plan: national administrative claims database, an outpatient laboratory testing inpatient hospital admissions database.Individuals 18-65 with continuous enrollment plan January 2019 to date diagnosis infection. Three comparator groups, matched by propensity score, individuals infected SARS-CoV-2: 2020 group, historical group viral lower respiratory tract illness.More than 50 (defined as first (index date) plus 21 days) were identified using ICD-10 (international classification diseases, 10th revision) codes. Excess four months hazard ratios Bonferroni corrected 95% confidence intervals calculated.14% ≤65 who (27 074 193 113) had at least one new type that required medical care illness, which was 4.95% higher group. The specific attributable SARS-Cov-2 phase, including chronic failure, cardiac arrythmia, hypercoagulability, encephalopathy, peripheral neuropathy, amnesia (memory difficulty), diabetes, liver test abnormalities, myocarditis, anxiety, fatigue, significantly greater three groups (2020, 2019, illness groups) (all P<0.001). Significant differences because ranged 0.02 2.26 per 100 people P<0.001), 1.24 25.65 compared group.The results indicate infection, types less commonly seen other illnesses. Although older, pre-existing conditions, admitted covid-19 greatest risk, younger (aged ≤50), those no or not also increased sequelae. is relevant healthcare planning.

Language: Английский

---

Psychiatric and neuropsychiatric sequelae of COVID-19 – A systematic review

Brain Behavior and Immunity, Journal Year: 2021, Volume and Issue: 97, P. 328 - 348

Published: July 30, 2021

It has become evident that coronavirus disease 2019 (COVID-19) a multi-organ pathology includes the brain and nervous system. Several studies have also reported acute psychiatric symptoms in COVID-19 patients. An increasing number of are suggesting deficits may persist after recovery from primary infection. In current systematic review, we provide an overview available evidence supply information on potential risk factors underlying biological mechanisms behind such sequelae. We performed search for sequelae patients using databases PubMed Embase. Included all contained follow-up period provided quantitative measures mental health. The was June 4th 2021. 1725 unique were identified. Of these, 66 met inclusion criteria included. Time to ranged immediately hospital discharge up 7 months discharge, participants spanned 3 266,586 participants. Forty anxiety and/or depression, 20 symptoms- or diagnoses post-traumatic stress disorder (PTSD), 27 cognitive deficits, 32 articles found fatigue at follow-up, sleep disturbances 23 studies. Highlighted severity, duration symptoms, female sex. One study showed abnormalities correlating with several inflammatory markers correlate symptoms. Overall, results this review suggest survivors but generally improve over time.

Language: Английский

---

Onset and frequency of depression in post-COVID-19 syndrome: A systematic review

Journal of Psychiatric Research, Journal Year: 2021, Volume and Issue: 144, P. 129 - 137

Published: Sept. 30, 2021

Language: Английский

---

Frequency, signs and symptoms, and criteria adopted for long COVID‐19: A systematic review

International Journal of Clinical Practice, Journal Year: 2021, Volume and Issue: 75(10)

Published: May 12, 2021

To identify, systematically evaluate and summarise the best available evidence on frequency of long COVID-19 (post-acute syndrome), its clinical manifestations, criteria used for diagnosis.

Language: Английский

---